1. Pharmaceutical and healthcare companies are among the top sponsors of inauguration parties welcoming the incoming Trump administration. They include Abbott Laboratories, Anthem, Bristol-Myers Squibb, Novo Nordisk, Mallinckrodt Pharmaceuticals, and Prudential. (The Intercept)

2. Abbas Hussain, GlaxoSmithKline’s president of global pharmaceuticals, will leave the company and be replaced by AstraZeneca EVP Luke Miels in April. Miel’s drug-development experience is expected to complement the consumer savvy of Emma Walmsley, who will succeed CEO Andrew Witty after he steps down on March 31. (MarketWatch)

3. Kaleo, the maker of EpiPen rival Auvi-Q, said its allergy auto-injector will return to the market on February 14 at no charge for people with commercial or government insurance. The drugmaker set Auvi-Q’s list price at $4,500. (Reuters)

4. Francis Collins, the director of the National Institutes of Health, will remain in his post when the Trump administration begins on Friday. It is unknown whether Trump will reappoint him permanently as NIH director. (Stat)

5. Pharmaceutical drug distributor McKesson agreed to pay $150 million in fines for failing to report “suspicious orders” of painkillers such as oxycodone from pharmacy clients. As part of the settlement, McKesson will also suspend sales of controlled substances from distribution centers in four states.